Asthma management on a mobile app
The app, available for $4.49 from iTunes for iPhones and iPads and $4.09 from Google Play for Android devices, is aimed at helping asthmatics follow their asthma action plan, providing active reminders to take medications or lung function tests and allowing the user to keep a journal of symptoms and recordings of peak flow and wheeze rate.
It also allows users to receive alerts when their asthma is "not well controlled" or "poorly controlled" – alerting them to a potential attack – add emergency contact information and review up to two months of medication use. The app will also allow asthmatics to share their data with doctors or family members.
iSonea plans to release future versions of AsthmaSense to incorporate its WheezoMeter device, which uses the company's acoustic respiratory monitoring (ARM) technology to measure wheezing. In future versions, the company plans to support other operating platforms and incorporate features such as a sensor that detects changes in environmental conditions such as air quality and weather.
The app has not yet been optimised for the Australian market, although an iSonea spokesperson said about half of the downloads for the app from iTunes have been from here. The emergency phone number provided is 911 rather than 000, and the height profile is still in feet and inches rather than centimetres.
“An updated version we are working on right now has these two aspects adjustable to where you live, so that it will provide the appropriate emergency number and switch to the metric system for height,” the spokesperson said. He said the height input was important for the peak flow calculator.
iSonea also recently announced a collaborative agreement with US company Qualcomm Life, which has developed a cloud-based data server called the 2net platform to collect and transmit patient health data from a range of medical devices.
iSonea and Qualcomm are collaborating to design and market a home and mobile asthma monitoring platform using iSonea's ARM devices on the 2net platform. The idea is to automatically and securely link patient asthma symptom and trend monitoring data to a cloud‐based portal for doctors to improve asthma management and outcomes.
The technology will ultimately allow doctors to securely access patient monitoring data, review treatment progress and medication adherence and adjust patient action plans accordingly. Family and caregivers will be able to view trends for reassurance about patient care.
The 2net platform is not currently available, but Qualcomm said 40 other medical device manufacturers are integrating with or considering the platform.
iSonea is the new name of KarmelSonix, an Israeli-Australian biotech company set up to develop acoustic monitoring technology for a range of respiratory diseases such as asthma and COPD. Now headquartered in the US, iSonea still has a base in Victoria and is listed on the Australian Stock Exchange.
It is currently developing two new devices: SonoSentry, an over-the-counter acoustic respiratory monitoring device that acts as a “thermometer” for wheezing; and AirSonea, a device that integrates WheezoMeter technology with Bluetooth and mobile health apps to help better manage asthma.
Posted in Australian eHealth